Alan De la Rosa , Wissam Ghusn , Daniel Sacoto , Alejandro Campos , Lizeth Cifuentes , Fauzi Feris , Bradley Busebee , Gerardo Calderon , Andres Acosta , Maria D. Hurtado
{"title":"三级体重管理中心在Covid-19大流行之前和期间使用抗肥胖药物减肥结果的比较","authors":"Alan De la Rosa , Wissam Ghusn , Daniel Sacoto , Alejandro Campos , Lizeth Cifuentes , Fauzi Feris , Bradley Busebee , Gerardo Calderon , Andres Acosta , Maria D. Hurtado","doi":"10.1016/j.obpill.2022.100046","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>/Objectives: Obesity is a risk factor for COVID-19 infection severity and mortality. Anti-obesity medications (AOM) are effective for weight loss. However, weight loss outcomes with AOM during the COVID-19 pandemic are yet to be described.</p></div><div><h3>Subjects</h3><p>/Methods: Between January 1, 2016, and June 30, 2021, a total of 966 patients were prescribed long-term FDA-approved AOMs at the Mayo Clinic. From these patients, 711 patients did not meet inclusion criteria. A total of 255 patients were included.</p></div><div><h3>Interventions/methods</h3><p>We performed a retrospective systematic review of electronic medical records and included patients who started a long-term FDA-approved AOM. We excluded patients with history of bariatric procedure, AOM prescription with lorcaserin, orlistat, semaglutide (approved for weight loss after the pandemic), or phentermine (short-term AOM), those taking ≥2 AOMs, <3 months of prescribed AOM, and/or pregnancy. Analysis was divided by 1)preCOVID-19: those who started an AOM before COVID-19 restrictions, 2)COVID-19: those who started an AOM during first quarter of 2020 after the establishment of COVID-19 restrictions. Our primary endpoint was the total body weight loss percentage (%TBWL) at 3, 6, and 12 months after AOM initiation.</p></div><div><h3>Results</h3><p>There was a statistical difference in TBWL% between the preCOVID-19 and COVID-19 group: 5.3 ± 3.5% vs 4 ± 3.0% (95% CI -2.4 to −0.2; p = 0.02) and 9.7 ± 7.2% vs 6.2 ± 4.7% (95% CI -5.7 to −1.3; p = 0.002) at 3 and 12 months, respectively. At 6 months, the TBWL% was 7.1 for the preCOVID-19 group compared to 6.2% for the COVID-19 (95% CI -2.5 to 0.7; p = 0.25).</p></div><div><h3>Conclusion</h3><p>With the possible exception of liraglutide, this study shows that weight loss outcomes to AOMs were inferior when prescribed during the routine clinical practice throughout COVID-19 pandemic, compared to the outcomes observed prior to the COVID-19 pandemic.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368122000377/pdfft?md5=9400c01d328cb71ff06daea4ffae7f36&pid=1-s2.0-S2667368122000377-main.pdf","citationCount":"1","resultStr":"{\"title\":\"A comparison between weight loss outcomes with anti-obesity medications before and during Covid-19 pandemic at a tertiary weight management center\",\"authors\":\"Alan De la Rosa , Wissam Ghusn , Daniel Sacoto , Alejandro Campos , Lizeth Cifuentes , Fauzi Feris , Bradley Busebee , Gerardo Calderon , Andres Acosta , Maria D. Hurtado\",\"doi\":\"10.1016/j.obpill.2022.100046\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>/Objectives: Obesity is a risk factor for COVID-19 infection severity and mortality. Anti-obesity medications (AOM) are effective for weight loss. However, weight loss outcomes with AOM during the COVID-19 pandemic are yet to be described.</p></div><div><h3>Subjects</h3><p>/Methods: Between January 1, 2016, and June 30, 2021, a total of 966 patients were prescribed long-term FDA-approved AOMs at the Mayo Clinic. From these patients, 711 patients did not meet inclusion criteria. A total of 255 patients were included.</p></div><div><h3>Interventions/methods</h3><p>We performed a retrospective systematic review of electronic medical records and included patients who started a long-term FDA-approved AOM. We excluded patients with history of bariatric procedure, AOM prescription with lorcaserin, orlistat, semaglutide (approved for weight loss after the pandemic), or phentermine (short-term AOM), those taking ≥2 AOMs, <3 months of prescribed AOM, and/or pregnancy. Analysis was divided by 1)preCOVID-19: those who started an AOM before COVID-19 restrictions, 2)COVID-19: those who started an AOM during first quarter of 2020 after the establishment of COVID-19 restrictions. Our primary endpoint was the total body weight loss percentage (%TBWL) at 3, 6, and 12 months after AOM initiation.</p></div><div><h3>Results</h3><p>There was a statistical difference in TBWL% between the preCOVID-19 and COVID-19 group: 5.3 ± 3.5% vs 4 ± 3.0% (95% CI -2.4 to −0.2; p = 0.02) and 9.7 ± 7.2% vs 6.2 ± 4.7% (95% CI -5.7 to −1.3; p = 0.002) at 3 and 12 months, respectively. At 6 months, the TBWL% was 7.1 for the preCOVID-19 group compared to 6.2% for the COVID-19 (95% CI -2.5 to 0.7; p = 0.25).</p></div><div><h3>Conclusion</h3><p>With the possible exception of liraglutide, this study shows that weight loss outcomes to AOMs were inferior when prescribed during the routine clinical practice throughout COVID-19 pandemic, compared to the outcomes observed prior to the COVID-19 pandemic.</p></div>\",\"PeriodicalId\":100977,\"journal\":{\"name\":\"Obesity Pillars\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2667368122000377/pdfft?md5=9400c01d328cb71ff06daea4ffae7f36&pid=1-s2.0-S2667368122000377-main.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obesity Pillars\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2667368122000377\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity Pillars","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667368122000377","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
摘要
背景/目的:肥胖是COVID-19感染严重程度和死亡率的危险因素。抗肥胖药物(AOM)对减肥很有效。然而，在COVID-19大流行期间，AOM的减肥效果尚未得到描述。对象/方法:在2016年1月1日至2021年6月30日期间，共有966名患者在梅奥诊所服用了经fda批准的长期AOMs。在这些患者中，有711例患者不符合纳入标准。共纳入255例患者。干预措施/方法我们对电子病历进行了回顾性系统评价，并纳入了开始长期fda批准的AOM的患者。我们排除了有减肥手术史、服用氯卡色林、奥利司他、西马鲁肽(大流行后批准用于减肥)或芬特明(短期AOM)的AOM处方、服用AOM≥2个月、服用AOM处方超过3个月和/或怀孕的患者。分析分为:1)COVID-19前:在COVID-19限制之前开始AOM的人;2)COVID-19:在COVID-19限制建立后的2020年第一季度开始AOM的人。我们的主要终点是AOM开始后3、6和12个月的总体重减轻百分比(%TBWL)。结果COVID-19前和COVID-19组TBWL%的差异有统计学意义:5.3±3.5% vs 4±3.0% (95% CI为-2.4 ~ - 0.2;p = 0.02)和9.7±7.2%和6.2±4.7% (95% CI -5.7−1.3;P = 0.002)，分别在3个月和12个月。在6个月时，COVID-19前组的TBWL%为7.1，而COVID-19组为6.2% (95% CI -2.5至0.7;p = 0.25)。结论本研究表明，在COVID-19大流行期间，与COVID-19大流行之前观察到的结果相比，在常规临床实践中使用利拉鲁肽的AOMs减肥结果较差。
A comparison between weight loss outcomes with anti-obesity medications before and during Covid-19 pandemic at a tertiary weight management center
Background
/Objectives: Obesity is a risk factor for COVID-19 infection severity and mortality. Anti-obesity medications (AOM) are effective for weight loss. However, weight loss outcomes with AOM during the COVID-19 pandemic are yet to be described.
Subjects
/Methods: Between January 1, 2016, and June 30, 2021, a total of 966 patients were prescribed long-term FDA-approved AOMs at the Mayo Clinic. From these patients, 711 patients did not meet inclusion criteria. A total of 255 patients were included.
Interventions/methods
We performed a retrospective systematic review of electronic medical records and included patients who started a long-term FDA-approved AOM. We excluded patients with history of bariatric procedure, AOM prescription with lorcaserin, orlistat, semaglutide (approved for weight loss after the pandemic), or phentermine (short-term AOM), those taking ≥2 AOMs, <3 months of prescribed AOM, and/or pregnancy. Analysis was divided by 1)preCOVID-19: those who started an AOM before COVID-19 restrictions, 2)COVID-19: those who started an AOM during first quarter of 2020 after the establishment of COVID-19 restrictions. Our primary endpoint was the total body weight loss percentage (%TBWL) at 3, 6, and 12 months after AOM initiation.
Results
There was a statistical difference in TBWL% between the preCOVID-19 and COVID-19 group: 5.3 ± 3.5% vs 4 ± 3.0% (95% CI -2.4 to −0.2; p = 0.02) and 9.7 ± 7.2% vs 6.2 ± 4.7% (95% CI -5.7 to −1.3; p = 0.002) at 3 and 12 months, respectively. At 6 months, the TBWL% was 7.1 for the preCOVID-19 group compared to 6.2% for the COVID-19 (95% CI -2.5 to 0.7; p = 0.25).
Conclusion
With the possible exception of liraglutide, this study shows that weight loss outcomes to AOMs were inferior when prescribed during the routine clinical practice throughout COVID-19 pandemic, compared to the outcomes observed prior to the COVID-19 pandemic.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
